The historical rank and industry rank for StemCell Institute's FCF Margin % or its related term are showing as below:
TSE:7096'
s FCF Margin % Range Over the Past 10 Years
Min: -16.12 Med: 5.36 Max: 35.96
Current: -16.12
During the past 9 years, the highest FCF Margin % of StemCell Institute was 35.96%. The lowest was -16.12%. And the median was 5.36%.
TSE:7096's FCF Margin % is ranked better than 65.26% of 950
companies
in the Biotechnology industry
Industry Median: -84.535
vs TSE:7096: -16.12
StemCell Institute FCF Margin % Related Terms
StemCell Institute FCF Margin % Historical Data
* Premium members only.
The historical data trend for StemCell Institute's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, StemCell Institute's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's FCF Margin % distribution charts can be found below:
* The bar in red indicates where StemCell Institute's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a FCF Margin % of -16.88% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on StemCell Institute and its competitors. According to the industry distribution chart, StemCell Institute ranks #330 out of 950 companies in the Biotechnology industry, placing it in the top 34.7%.
Is StemCell Institute's FCF Margin % too high?
StemCell Institute's current FCF Margin % is -16.88%. Based on the distribution chart, StemCell Institute ranks #330 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #330 out of 950 companies for FCF Margin %. This puts StemCell Institute in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on StemCell Institute and its competitors. StemCell Institute's current FCF Margin % is -16.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.82, compared to a current price of 円768.00 — trading 57.7% below its estimated fair value. The current FCF Margin % is -16.88%. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current FCF Margin % is -16.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.7% below its estimated GF Value™ of 円1,813.82.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
FCF Margin %: -16.88%
GF Value™: 円1,813.82 vs. price of 円768.00 (57.7% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
